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Over the past 6 years, autologous haemopoietic stem cell transplantation (HSCT) has been suggested as a possible therapeutic option in patients with severe autoimmune diseases. Numerous phase II trials have demonstrated encouraging results, with over 70 patients worldwide now having undergone HSCT for rheumatoid arthritis (RA).
Initial trials in RA have demonstrated significant responses with over two-thirds of patients achieving a 50% improvement in disease activity as measured by American College of Rheumatology (ACR) criteria. 1 However, responses in RA have not been as consistently sustained as in other diseases, with improvement in disease generally lasting for 6 months to 2 years. This is in marked contrast to other diseases such as systemic lupus erythematosis (SLE) 2 where disease control has been demonstrated for up to 5 years. It has been noted by several groups that once disease recurrence occurs in RA there is often a rapid response to reintroduction of disease-modifying agents, suggesting that HSCT induces a form of immunomodulation that may be manipulated by other medications as a form of maintenance treatment. 3, 4 There is increasing evidence that the responses attained in RA patients during HSCT (using 200 mg/kg cyclophosphamide) may be related to B-cell depletion and removal of the putative autoantibody, rheumatoid factor (RF). In a previous trial conducted by our group, it was demonstrated that there was a temporal relationship between B-cell reconstitution and recurrence of disease post HSCT suggesting a role for the B-cell lineage in disease pathophysiology. It was also noted in this trial that patients with a low titre of RF (o100 IU/l) had a more sustained response and that an increasing RF titre heralded the onset of disease recurrence in 72% of patients. 3 Based on these data, we hypothesized that B-cell depleting therapy would be an effective therapeutic option to eradicate the autoreactive B-cell population in RA. The recent introduction of Rituximab, an anti-CD20 antibody, made it possible to test this hypothesis. Edwards et al 5 previously demonstrated in a pilot study that Rituximab combined with cyclophosphamide may have significant efficacy in RA. Cyclophosphamide may confer a currently unexplained synergistic action with Rituximab that may be important in the mechanism of the response. Given that our patients had previously received large doses of cyclophosphamide, we hypothesized that further cyclophosphamide would not be required. We thus initiated this phase II trial of Rituximab in 10 patients with severe RA who had recurrence of disease post HSCT in order to assess its efficacy and safety in this setting.
Patients, materials and methods

Patient selection
Patients who had received a HSCT for severe RA were eligible to enter this study provided they were not pregnant, had no serious underlying infection and had a clinical recurrence of RA with documented disease activity. Patients had not received TNFa antagonists as they were unavailable in Australia during the study period. Patients aged 18-65 years were eligible if they met the 1987 ACR criteria for classification of rheumatoid arthritis 6 and had active disease as defined by six or more swollen and tender joints with at least two of the following: 45 min or more of joint stiffness, CRP41.5 mg/dl or an erythrocyte sedimentation rate (ESR)420 mm/h. Exclusion criteria included severe psychiatric disease or uncontrolled cardiac, renal or hepatic failure. Patients who had severe previous infections with encapsulated organisms or those who were hypogammaglobulinaemic (defined as IgG o5.6 g/l) were also excluded. The patients were selected from two centres that had performed 25 HSCT procedures for RA over the proceeding 4 years. All patients remained on their DMARDs and prednisone medications during the first 2 months of the trial and then had the option of reducing the dose or ceasing them. The trial was approved by the institutional ethics committee in both centres and was conducted in accordance with the declaration of Helsinki and the Australian National Health and Medical Research Council statement on human experimentation.
Trial design
The trial was a Phase II trial designed to assess the efficacy and safety of Rituximab post HSCT in patients with RA. Baseline was considered the visit prior to commencement of Rituximab where ACR core criteria investigations and blood tests were performed (including joint counts, ESR, CRP, health assessment questionnaire (HAQ) and visual analogue scales). The first infusion of Rituximab occurred within 2 weeks of this visit and the second 2 weeks later. All eligible patients received Rituximab 2 Â 1 g by intravenous infusion 2 weeks apart. On the day of each infusion of Rituximab, patients received i.v. 250 mg Methylprednisolone. The month of the Rituximab infusions was considered month 1, and patients were subsequently reviewed monthly until 12 months. Patients were also reviewed at recurrence of disease as defined by: an increase in Prednisone dose 450% or introduction of a new DMARD any time after month 2 or progression of disease such that there was a return to o20% improvement on two successive monthly visits. If a patient had a recurrence of disease, then review was continued every month until 12 months. DMARDs were continued at the current dose for the first 2 months post Rituximab. Corticosteroids could be increased if required during Rituximab therapy but if the increase was greater than 50% from baseline any time from 2 months post Rituximab, a patient would be considered a nonresponder according to ACR criteria. A major response was defined as ACR 50 or greater (i.e. an improvement of 50% or more in swollen and tender joint counts plus a 50% improvement in 3/5 other criteria such as CRP, HAQ, patient visual analogue scale, physician visual analogue scale and pain visual analogue scale 7 ). At baseline and at each follow-up visit, all patients were assessed for all ACR criteria 7 including: swollen and tender joint counts, visual analogue scales for pain, disease activity as assessed by both patient and physician, ESR, CRP and HAQ. Baseline FBC, biochemistry, viral serology and immunoglobulin/paraprotein levels were estimated monthly. Immune reconstitution parameters were performed at baseline, 3, 6, 9 and 12 months post Rituximab using fluorescent monoclonal antibodies to CD4, 8, 19, 20, 4/45RA, 4/45RO. B cells were defined as CD19 þ or CD20 þ lymphocytes based on forward and side scatter properties.
The primary end point was the number of patients attaining ACR 50 (i.e. a 50% improvement in 5/7 ACR criteria between baseline and follow-up) at 6 months post Rituximab. Secondary end points were duration of response (time4ACR 50 from baseline), and change in baseline for individual ACR criteria, RF titre and B-cell numbers/B-cell phenotype. Safety analysis at each month post Rituximab was also a secondary end point.
Adverse events
All serious adverse events (SAE) were reported to Roche pharmaceuticals and the local institutional ethics committee within 24 h. An SAE was defined as any clinical experience that was fatal, life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/ incapacity or a congenital anomaly/birth defect.
Statistical analysis
All figures express data as the mean7standard error of the mean (s.e.m.). For comparison between baseline and subsequent months of follow-up, the Wilcoxon Sign rank test (for nonparametric data) was used with P-values o0.05 considered significant. All analyses were conducted on SAS version 8 or Prism version 3 software.
Results
Patient demographics
Baseline demographic and disease criteria are outlined in Table 1 . A total of 10 patients (eight female and two male subjects), with a median age of 46.5 years (range: 25-61), entered this trial in two centres. Nine patients had received 200 mg/kg cyclophosphamide with stem cell rescue at a median of 25 months (range: 16-37) previously. One patient had received cyclophosphamide 100 mg/kg, 47 months previously during an earlier pilot trial. 8 The median disease duration was 10 years (range: 5-18) and the median number of previous DMARDs was 5 (range: 3-8). Five patients were receiving corticosteroids at a median dose of 10 mg (range: 8-20 mg). Nine patients were RF positive with a median titre of 216 IU/ml (range: 35-3800 IU/ml). The first patient entered the trial in March 2001 and the last patient in the main study was treated in January 2002. All 10 patients received both doses of Rituximab and Methylprednisolone. Two patients withdrew from the trial at 8 months post treatment upon disease recurrence after initial ACR 50-70 responses -both patients were subsequently retreated with Rituximab to maintain responses.
Efficacy as measured by ACR criteria
Rituximab was efficacious as judged by ACR criteria, with 9/10 (90%) patients achieving significant responses. During follow-up, 5/10 (50%) patients achieved an ACR 70 response, three patients (30%) achieved ACR 50 and one patient achieved an ACR 20. One patient failed to achieve an ACR response during the 12-month follow-up. Overall, there was a significant reduction in swollen and tender joint counts post Rituximab, as illustrated in Figure 1 . Likewise, markers of inflammation such as the ESR and CRP showed a significant reduction post Rituximab compared to baseline as illustrated in Figure 2 . Other ACR criteria such as the HAQ, pain score, patient and physician global assessment scores are illustrated in Figure 3 , demonstrating the significant responses attained in these patients. All five patients on prednisone reduced their doses of corticosteroid during the 12-month follow-up period.
The primary end point of this study (the proportion of patients achieving ACR 50 status at six months) was a 50% ACR 50. The maximal response rates were attained between months 5 and 8 as illustrated in Figure 4 . The mean time to ACR 50 was 144 days with only one patient attaining an ACR 50 response before 3 months. Disease responses appeared to taper after month 8 with 6/9 (66%) responding patients experiencing recurrence of disease at months 7-12. The remaining three patients remained under disease control at 12 months with two ACR 20 and one ACR 50. Four patients who have undergone retreatment with Rituximab are still undergoing follow-up but a preliminary analysis suggests a similar response rate has been attained.
Immune reconstitution and rheumatoid factor
Rheumatoid factor was reduced in all RF-positive patients. There was a 74% reduction of RF at 3 months reducing to 64% at 6 months and 41% at 9 months -see Figure 5 . In all, 3/10 patients became RF negative (defined as RF o20 IU/ml) after Rituximab therapy. However, two of the three subsequently reverted to RF positivity. All patients who responded had a reduction in their RF titre. RF rose within 1 month of recurrence of disease in all five evaluable patients (three patients are still responding, one is RF negative and one was a nonresponder). B cells reconstituted to pre-Rituximab levels before a rise in RF in 3/5 patients.
B-cell reconstitution studies revealed that CD20 B cells were significantly depleted by Rituximab at 3 and 6 months (P ¼ 0.002, P ¼ 0.004, respectively) -see Figure 5 . Patients remained B cell depleted until 6 months when there was a gradual reconstitution to baseline levels at 9-12 months. CD19 B-cell reconstitution demonstrated the same pattern suggesting no confounding effect of the Rituximab on CD20 numbers (data not shown). The majority of B cells expressed CD40 and HLADR before Rituximab and this pattern did not change upon reconstitution.
Baseline CD4:8 ratio was 1.09. CD4 and CD8 T cells were not depleted by the Rituximab infusion; however, there was a significant rise in CD4 T cells at 6 months (P ¼ 0.04). Both T-cell subsets returned to baseline levels at 12 months. Both naive and memory T cells were not significantly altered by the administration of Rituximab. 
Safety and tolerability of Mabthera infusions
All patients received all doses of Rituximab as per the planned schedule. The Rituximab infusion was well tolerated in all the patients with only mild side effects noted including nausea (two patients), fever, headache, rash and flushing occurring in one patient each, respectively. No episodes of hypotension or rigors were observed during the infusion. There was no increased toxicity upon rechallenge in four patients given a second schedule of Rituximab.
Overall, there was no significant reduction in IgG, IgA levels in 9/10 patients during the 12 month follow-up period. One patient experienced a reduction in IgG requiring immunoglobulin replacement (see below). There was a mild reduction in overall IgM levels during the study period (Po0.05 at months 1, 3, 6 compared to baseline). No paraproteins developed during this period. In the 12-month follow-up period, several minor infectious episodes occurred in five patients as listed in Table 2 . One major infection and numerous other complications unrelated to Mabthera occurred in one patient. A 61-year-old man had sustained a stress fracture of his tibia immediately before the Rituximab infusion requiring a plaster cast. Subsequently he developed a pressure ulcer complicated by osteomyelitis due to methicillin resistant Staph Aureus. He required prolonged antibiotic therapy and Intragam infusions for 6 months for a mild reduction in his serum IgG (7.6 g/l pre-infusion to 3.9 g/l at 3 months). He subsequently underwent an open reduction and external fixation procedure to the fracture site and has made a good recovery. This patient also experienced a deep venous thrombosis and transient ischaemic attack during this illness.
Discussion
In this pilot study, Rituximab was very successful in producing clinical responses in RA patients who had recurrent disease post HSCT, with 80% of patients achieving major responses (ACR responses of 50 or 70% improvement). These encouraging results, in subjects with severe resistant disease, are comparable to the results attained with HSCT or other biological therapies such as TNFa antagonists. 9 Larger multicentre controlled studies currently recruiting RA patients who have not received a prior HSCT will be required to confirm these results. The temporal relationship between disappearance of RF and B-cell lymphopenia, with clinical response, suggests that targeted therapy against autoreactive B-cells clones is the mechanism of response in these patients. Further evidence that ablation of B cells and RF are central to the response seen in this trial are provided by the immune reconstitution data which demonstrate that no other cell group was depleted by the treatment regimen. We have previously demonstrated that B-cell depletion appeared to contribute to the responses seen after HSCT 3. The results of this pilot study would appear to provide further evidence for this hypothesis. The pattern of reconstitution of RF and B cells is similar to the HSCT trial in that response and recurrence are more closely related to RF depletion than B-cell reconstitution.
The successful retreatment of four patients not only provided important safety data for repeated administration of Rituximab in this patient population but also confirmed that a reduction in B cells and RF corresponds to a response in RA. This observation has been seen in those responding to methotrexate 10 and the pan-lymphocyte depleting antibody (Campath -anti-CD52) 11 where response was only evident during B-cell lymphopenia.
It is possible that cyclophosphamide contributes to the effect seen in these patients because Leandro et al 12 have previously reported cases where Rituximab alone appeared not to be effective in RA patients. Cyclophosphamide, in addition to its B-cell depleting properties, may have other immunosuppressive properties, such as an effect on T-cell costimulation, as has been demonstrated in SLE patients. 13 In this study, cyclophosphamide had been given at a median of 25 months earlier as part of HSCT conditioning but the patients still had markedly reduced naı¨ve T-cell numbers (data not shown) and an inverted CD4:8 14 there is evidence in other diseases such as Multiple Sclerosis that this effect of cyclophosphamide is prolonged. 15 For this reason and in the interests of safety, no further cyclophosphamide was given to these patients but corticosteroids were given to temporarily ablate plasma cells as a possible source of RF. The delayed time to major ACR response (43 months) suggests that the corticosteroid was not the primary agent responsible for the sustained disease improvement in this study. This is supported by randomized trials of pulse methylprednisolone that have demonstrated only brief (4-8 weeks) responses in most patients. 16 Previously published studies of Rituximab administration to patients with RA have been in the context of failure to methotrexate or other DMARDs. 5, 17, 12 The response of patients treated with cyclophosphamide and Rituximab by Edwards and Cambridge 5 appears to be more sustained than that demonstrated in this trial suggesting that the benefit of cyclophosphamide may be more potent closer to Rituximab administration rather than 2 years later, as in this study. A recent trial using Rituximab alone 17 in RA patients resulted in less substantial and shorter responses than in this study suggesting that the optimal approach is to combine other agents such as cyclophosphamide with Rituximab to gain maximal Bcell depletion.
Rituximab therapy in this heavily pre-treated population was safe, with minimal adverse events. There were no major adverse effects during the infusion and only one serious infection developed subsequently which was probably caused by other factors. It is possible that the main reason for the lack of infectious complications is that IgG and IgA levels generally remained within normal ranges throughout the 12-month follow-up phase.
In summary, this study has provided further evidence for the suggestion that autoreactive B-cell clones play an important role in the pathogenesis of RA. This trial has demonstrated that post HSCT, RA patients can respond to agents rapidly, as has been suggested previously. The mechanism of this immunomodulation post HSCT is currently unexplained but depletion of B cells is one possibility. Currently, it is our opinion that HSCT should be reserved for patients who have failed standard care, including TNFa antagonists, as has been outlined in the EBMT ASTIRA trial. It is possible that Rituximab may also be considered standard of care if current randomized trials show a benefit. Nevertheless, there is still approximately 30% of RA patients who would be eligible for HSCT based on the TNFa antagonist data. It is in this group of severe, resistant patients that Rituximab may be used in either the conditioning as an additional B-cell depleting agent or post HSCT as a maintenance agent given the high recurrence rate post HSCT in RA. One could postulate that HSCT 'de-bulks' the B-cell clones in the lymphoid follicles of the RA synovium analogous to highdose therapy in non-Hodgkin's lymphoma and it is possible that Rituximab could be valuable in enhancing this effect. Further trials are warranted to explore this possibility based on the safety and efficacy data presented in this study.
